Paula M. Fracasso
- BA, Biology and Classics, College of the Holy Cross, Worcester, MA
- MD, Medicine, Yale University School of Medicine, New Haven, CT
- PhD, Pharmacology, Yale University Graduate School, New Haven, CT
- Medical Internship, Internal Medicine, Beth Israel Hospital, Boston, MA
- Medical Residency, Internal Medicine, Beth Israel Hospital, Boston, MA
- Research Fellowship, Molecular Biology, Massachusetts Institute of Technology, Boston, MA
- Clinical Fellowship, Hematology and Oncology, Tufts University, Boston, MA
EGFR and cell cycle inhibitors in women's malignancies.
Dr. Paula M. Fracasso, the Lawrence W. Penniston, M.D., Family Professor of Women’s Oncology Research, is the Deputy Director of the Cancer Center and the Section Chief of Medical Oncology. Dr. Fracasso's clinical research involves early drug development with an emphasis on women’s cancers. She is the Principal Investigator of a NCI R21 Quick Trials grant which explores the use of an investigational cell cycle inhibitor, UCN-01, in combination with irinotecan in women with in triple negative (estrogen and progesterone receptor and HER2 negative) advanced breast. She is also interested in EGFR inhibitors in combination with chemoradiation in locally advanced cervix cancer. She is the national chair of the Phase I Subcommittee and co-chair of the Developmental Therapeutics Committee in the National Cancer Institute’s Gynecologic Oncology Group (GOG) which is responsible for developing new therapies for women with gynecologic malignancies. She is a member of NCI's Operational Efficiency Working Group of the Clinical Trials Advisory Committee charged with implementing processes to reduce the time for activation of NCI-supported clinical trials.